Product portfolio

Molecular Diagnostics

Transforming testing & treatment together

Giving you confidence in the performance of our systems and assays in your laboratory

 

Our commitment to quality

 

As pioneers of polymerase chain reaction (PCR) technology, we continue to demonstrate our commitment to scientific and clinical excellence. Roche systems and assays are the trusted choice in clinical trials across the industry —from plasma and blood screening and viral load testing to more recent leadership with HPV Primary Screening and advances in oncology testing with the cobas® EGFR Mutation Test v2. We hold our products to the highest performance standards to give you confidence in every result.

Advanced assay design

 

Our unrivaled investment in research and development allows us to stay ahead of constantly evolving diseases, lets you inform the best possible treatment decisions, and ensures we can keep the blood supply safe for all. Through an unrelenting dedication to innovation, Roche consistently delivers industry leading breakthroughs:

1

Pioneered the dual target approach for HIV-1 viral load monitoring

RMD_Molecular Home_Screening_Icon536

Developed the only clinically validated, FDA-approved and CE-marked assay for first-line, primary screening of cervical cancer

1

Our cobas® EGFR v2 test allows you to detect EGFR mutations in plasma and FFPE tissue to determine mutation status

1

Real-time detection and discrimination of HIV, HCV, and HBV in a single test for blood donor screening

Ensuring confidence in results

 

Results generated on Roche systems are proven to be standardised and comparable across all platforms1*. The performance of new assays is verified with high precision across platforms for accuracy and traceability according to World Health Organization (WHO) standards.

1

Comprehensive solutions to meet your molecular testing needs

References

  1. Performance evaluation of the new real-time PCR-based cobas® HCV assay for use on the cobas® 6800/8800 systems for the detection and quantification of HCV RNA - RING Study. Poster presented at AASLD, Nov 11-14, 2016, Boston, MA, USA.
  2. Iordanoaia N, et al. Cross-contamination compliance of cobas p 612 pre-analytical system in use with cobas® 6800/8800 Systems. Declaration of Serology and NAT testing compliance. Poster presented at ISBT, Dubai, UAE, 2016 September.
Filter